Peer-Reviewed: Demonstrating the Emerging Case for Ivermectin Targeting COVID-19

Peer-Reviewed Demonstrating the Emerging Case for Ivermectin Targeting COVID-19

The Front Line COVID-19 Critical Care Alliance (FLCCC) recently presented their meta-analysis of randomized controlled trials involving Ivermectin as a treatment option for COVID-19 to the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel. A few weeks prior, this same group of physicians/researchers presented a similar themes presentation to the U.S. Senate. With a growing number of ivermectin-focused randomized controlled trials around the world, public research agencies’ interest has perked up. Despite vaccines now authorized under emergency use, early onset treatment options are still necessary. The U.S. government continues to pour money into expensive novel monoclonal antibody development recently placing $486 million to develop novel COVID-19 therapies—clearly the need is present, and imminent, with such amounts of money involved. Now the peer-reviewed frontiers in Pharmacology has published an important manuscript authored by FLCCC members Dr. Kory and Dr. Paul Marik as well as a group of esteemed colleagues from the United States and Europe reporting on emerging case evidence for ivermectin. The accomplished physician/researchers w...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee